Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection

Shock

Volumn 33, Issue 1, 2010, Pages 24-30

  Herrmann, Jeremy L ^a   Wang, Yue ^a   Abarbanell, Aaron M ^a   Weil, Brent R ^a   Tan, Jiangning ^a   Meldrum, Daniel R ^a,b,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b Department of Surgery ^*  (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

I R injury; Inflammation; Isolated heart perfusion; Myocardial ischemia; Stem cell therapy

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPOXIA; INFLAMMATION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PROTEIN ANALYSIS; REPERFUSION INJURY; STEM CELL TRANSPLANTATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CASPASE 3; CELLS, CULTURED; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73849142463     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181b7d137     Document Type: Article

References (42)

1. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44: 1690-1699, 2004.
2. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, et al.: Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance STelevation infarct regeneration) trial. Circulation 113:1287-1294, 2006.
3. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F: Muscle regeneration by bone marrowYderived myogenic progenitors. Science 279:1528-1530, 1998.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147, 1999.
5. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ: Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 73:1919-1925, 2002; discussion 1926.
6. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ: Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9:1195-1201, 2003.
7. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, et al.: Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 102:11474-11479, 2005.
8. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98: 10344-10349, 2001.
9. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, et al.: Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705, 1999.
10. Hsieh PC, Segers VF, Davis ME, MacGillivray C, Gannon J, Molkentin JD, Robbins J, Lee RT: Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13:970-974, 2007.
11. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI: Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 80:229-236, 2005; discussion 236-237.
12. Crisostomo PR, Wang M, Markel TA, Lahm T, Abarbanell AM, Herrmann JL, Meldrum DR: Stem cell mechanisms and paracrine effects: potential in cardiac surgery. Shock 28:375-383, 2007.
13. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 274: R577-R595, 1998.
14. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, et al.: Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367-368, 2005.
15. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE: Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94:678-685, 2004.
16. Uemura R, Xu M, Ahmad N, Ashraf M: Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98:1414-1421, 2006.
17. Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F: Fate of cultureexpanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res 104:398-402, 2009.
18. Marquardt H, Hunkapiller MW, Hood LE, Todaro GJ: Rat transforming growth factor type 1: structure and relation to epidermal growth factor. Science 223:1079-1082, 1984.
19. Teixido J, Gilmore R, Lee DC, Massague J: Integral membrane glycoprotein properties of the prohormone pro-transforming growth factor-alpha. Nature 326:883-885, 1987.
20. Coffey RJ Jr, Derynck R, Wilcox JN, Bringman TS, Goustin AS, Moses HL, Pittelkow MR: Production and auto-induction of transforming growth factorY alpha in human keratinocytes. Nature 328:817-820, 1987.
21. Wilcox JN, Derynck R: Localization of cells synthesizing transforming growth factorYalpha mRNA in the mouse brain. J Neurosci 8:1901-1904, 1988.
22. Lemarie CA, Tharaux PL, Esposito B, Tedgui A, Lehoux S: Transforming growth factorYalpha mediates nuclear factor kappaB activation in strained arteries. Circ Res 99:434-441, 2006.
23. Sheng G, Guo J, Warner BW: Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 293: G599-G606, 2007.
24. Rappolee DA, Mark D, Banda MJ, Werb Z: Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. Science 241:708-712, 1988.
25. Satomura K, Derubeis AR, Fedarko NS, Ibaraki-O'Connor K, Kuznetsov SA, Rowe DW, Young MF, Gehron Robey P: Receptor tyrosine kinase expression in human bone marrow stromal cells. J Cell Physiol 177:426-438, 1998.
26. Tamama K, Fan VH, Griffith LG, Blair HC, Wells A: Epidermal growth factor as a candidate for ex vivo expansion of bone marrowYderived mesenchymal stem cells. Stem Cells 24:686-695, 2006.
27. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ: Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103:1662-1668, 2004.
28. Sun S, Guo Z, Xiao X, Liu B, Liu X, Tang PH, Mao N: Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 21:527-535, 2003.
29. Wang M, Sankula R, Tsai BM, Meldrum KK, Turrentine M, March KL, Brown JW, Dinarello CA, Meldrum DR: P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock 21:170-174, 2004.
30. Wang M, Tsai BM, Kher A, Baker LB, Wairiuko GM, Meldrum DR: Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. Am J Physiol Heart Circ Physiol 288:H221-H226, 2005.
31. Crisostomo PR, Markel TA, Wang M, Lahm T, Lillemoe KD, Meldrum DR: In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery 142:215-221, 2007.
32. Wang M, Tsai BM, Crisostomo PR, Meldrum DR: Pretreatment with adult progenitor cells improves recovery and decreases native myocardial proinflammatory signaling after ischemia. Shock 25:454-459, 2006.
33. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, et al.: Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20:661-669, 2006.
34. Hiasa K, Egashira K, Kitamoto S, Ishibashi M, Inoue S, Ni W, Zhao Q, Nagata S, Katoh M, Sata M, et al.: Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor. Basic Res Cardiol 99:165-172, 2004.
35. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, Yang YZ, Pan C, Ge J, Phillips MI: Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 117:3-10, 2004.
36. Wang Y, Haider HK, Ahmad N, Xu M, Ge R, Ashraf M: Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells over-expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol 40:736-745, 2006.
37. Yang J, Zhou W, Zheng W, Ma Y, Lin L, Tang T, Liu J, Yu J, Zhou X, Hu J: Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 107:17-29, 2007.
38. Guzman MJ, Crisostomo PR, Wang M, Markel TA, Wang Y, Meldrum DR: Vascular endothelial growth factor improves myocardial functional recovery following ischemia/reperfusion injury. J Surg Res 150:286-292, 2008.
39. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA: Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 98:2871-2876, 2001.
40. Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV: Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol 269:R229-R235, 1995.
41. Adachi S, Natsume H, Yamauchi J, Matsushima-Nishiwaki R, Joe AK, Moriwaki H, Kozawa O: p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. Cancer Lett 277:108-113, 2009.
42. Wang M, Zhang W, Crisostomo P, Markel T, Meldrum KK, Fu XY, Meldrum DR: STAT3 mediates bone marrow mesenchymal stem cell VEGF production. J Mol Cell Cardiol 42:1009-1015, 2007.